Switch to: Citations

Add references

You must login to add references.
  1. Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Off-label prescribing is an integral part of contemporary medicine. Many patients benefit when they receive drugs or devices under circumstances not specified on the label approved by the Food and Drug Administration. An off-label use may provide the best available intervention for a patient, as well as the standard of care for a particular health problem. In oncology, pediatrics, geriatrics, obstetrics, and other practice areas, patient care could not proceed without off-label prescribing. When scientific and medical evidence justify off-label uses, (...)
    Download  
     
    Export citation  
     
    Bookmark   14 citations  
  • Examining the Ethics of Clinical Use of Unproven Interventions Outside of Clinical Trials During the Ebola Epidemic.Seema K. Shah, David Wendler & Marion Danis - 2015 - American Journal of Bioethics 15 (4):11-16.
    The recent Ebola outbreak in West Africa began in the spring of 2014 and has since caused the deaths of over 6,000 people. Since there are no approved treatments or prevention modalities specifically targeted at Ebola Virus Disease , debate has focused on whether unproven interventions should be offered to Ebola patients outside of clinical trials. Those engaged in the debate have responded rapidly to a complex and evolving crisis, however, and this debate has not provided much opportunity for in-depth (...)
    Download  
     
    Export citation  
     
    Bookmark   8 citations  
  • Off-Label Prescribing: A Call for Heightened Professional and Government Oversight.Rebecca Dresser & Joel Frader - 2009 - Journal of Law, Medicine and Ethics 37 (3):476-486.
    Under current U.S. law, physicians may prescribe drugs and devices in situations not covered on the label approved by the Food and Drug Administration. Those supporting this system say that requiring FDA approval for off-label uses would unnecessarily impede the delivery of benefits to patients. Patients do benefit from off-label prescribing that is supported by sound scientific and medical evidence. In the absence of such evidence, however, off-label prescribing can expose patients to risky and ineffective treatments. The medical community and (...)
    Download  
     
    Export citation  
     
    Bookmark   14 citations  
  • Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways.Holly Fernandez Lynch & Alison Bateman-House - 2020 - Journal of Law, Medicine and Ethics 48 (2):365-372.
    Download  
     
    Export citation  
     
    Bookmark   7 citations